<DOC>
	<DOCNO>NCT02005783</DOCNO>
	<brief_summary>To evaluate EC/TC ( epirubicin cyclophosphomide docetaxel cyclophosphomide ) EC/TC plus DBD ( Danggui Buxue Decoction ) adjuvant treatment breast cancer patient . The aim evaluate whether DBD decrease incidence grade 3/4 neutropenia induce EC/TC regimen chemotherapy .</brief_summary>
	<brief_title>Study Danggui Buxue Decoction Preventing Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Women age ≥18 year &lt; 70 year ; Histologically confirm invasive breast cancer core needle biopsy , suggest receive EC/TC regiment adjuvant chemotherapy MDT ; Leukocyte ≥ 3*109/L ; Neutrophil ≥ 1.5*109/L ; PLT ≥ 100*109/L ; Serum AST/SGOT ALT/AGPT ≤ 2.5 time upper limit normal ( UNL ) range Serum creatinine/BUN ≤ upper limit normal ( UNL ) range ; No dysphagia , able take Danggui Buxue Decoction ( DBD ) Written inform consent accord local ethic committee requirement . Has ECOG Performance Score 01 ; Metastatic breast cancer ; Family history endometrial cancer kind gynecologic cancer ; Patients severe comorbidity indicate intolerant adjuvant chemotherapy ; patient psychiatric disorder disease lead incompliance therapy ; Known severe hypersensitivity drug study ; Prior adjuvant chemotherapy kind cancer ; Hematologic disorder relative aplasia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>incidence grade 3/4 neutropenia</keyword>
	<keyword>incidence febrile neutropenia</keyword>
	<keyword>time neutropenia recovery</keyword>
	<keyword>safety</keyword>
</DOC>